Innate Pharma SA
IPHA · XNASCIK 1598599fmd_1P7P9FRGRZ3R6XKGKAX67SQGV3Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2017 to Dec 31, 2025, 15 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 44 | 94 | 85 | 70 | 25 | 58 | 62 | 20 | 9 |
| Research and development | 67 | 70 | 63 | 50 | 47 | 52 | 56 | 52 | 44 |
| Selling, general and administrative | 17 | 18 | 21 | 19 | 26 | 22 | 18 | 20 | – |
| Operating income | (40) | 5 | 2 | 1 | (48) | (57) | (13) | (52) | (54) |
| Interest expense | 11 | 8 | 5 | 7 | 4 | 5 | 2 | 4 | 3 |
| Income before taxes | (48) | 3 | 8 | (1) | (45) | (58) | (8) | (49) | (49) |
| Income tax expense | 0 | (0) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (48) | 3 | 8 | (1) | (45) | (58) | (8) | (49) | (49) |
| Net income | (48) | 3 | (21) | (64) | (53) | (58) | (8) | (49) | (49) |